HIGHLIGHTS
- who: Ji Eun Shin and colleagues from the United States University of Verona, Italy have published the Article: Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report, in the Journal: (JOURNAL)
SUMMARY
PDAC is one of the most lethal diseases, with the 5-year survival rate remaining as low as 6% in the USA. As mentioned above, BRAF NVTAP deletion is reported as an oncogenic mutation in PDAC. There was a single previous case where dabrafenib was used to target BRAF NVTAP deletion, and the clinical effectiveness . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.